aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2025. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
From TechCrunch
By Marina Temkin
April 25, 2024
Advances in generative AI have taken the tech world by storm. Biotech investors are making a big bet that similar computational methods could revolutionize drug discovery.
On Tuesday, ARCH Venture Partners and Foresite Labs, an affiliate of Foresite Capital, announced that they incubated Xaira Therapeutics and funded the AI biotech with $1 billion. Other investors in the new company, which has been operating in stealth mode for about six months, include F-Prime, NEA, Sequoia Capital, Lux Capital, Lightspeed Venture Partners, Menlo Ventures, Two Sigma Ventures and SV Angel.
Xaira’s CEO Marc Tessier-Lavigne, a former Stanford president and chief scientific officer at Genentech, says the company is ready to start developing drugs that were impossible to make without recent breakthroughs in AI. “We’ve done such a large capital raise because we believe the technology is at an inflection point where it can have a transformative effect on the field,” he said.
The advances in foundational models come from the University of Washington’s Institute of Protein Design, run by David Baker, one of Xaira’s co-founders. These models are similar to diffusion models that power image generators like OpenAI’s DALL-E and Midjourney. But rather than creating art, Baker’s models aim to design molecular structures that can be made in a three-dimensional, physical world.
While Xaira’s investors are convinced that the company can revolutionize data design, they emphasized that generative AI applications in biology are still in the early innings.
Vik Bajaj, CEO of Foresite Labs and managing director of Foresite Capital, said that unlike in technology, where data that train AI models is created by consumers, biology and medicine are “data poor. You have to create the datasets that drive model development.”
Other biotech companies using generative AI to design drugs include Recursion, which went public in 2021, and Genesis Therapeutics, a startup that last year raised a $200 million Series B co-led by Andreessen Horowitz.
The company declined to say when it expects to have its first drug available for human trials. However, ARCH Venture Partners managing director Bob Nelsen underscored that Xaira and its investors are ready to play the long game.
“You need billions of dollars to be a real drug company and also think AI. Both of those are expensive disciplines,” he said.
Xaira wants to position itself as a powerhouse of AI drug discovery. However, some view bringing on Tessier-Lavigne as CEO as an unexpected move. Tessier-Lavigne resigned just seven months ago from his position as Stanford president following explosive reports — including in the Stanford Daily — that his laboratory at Genetech had manipulated research data.
Tessier-Lavigne was not himself accused of manipulating any data and denied knowing there was falsified research being published by his colleagues.
Indeed, after a special committee of Stanford’s Board of Trustees initiated a review related to Tessier-Lavigne’s scientific research, he let it be known that the panel concluded he “did not engage in any fraud or falsification of scientific data.” Still, as he wrote in his last public communication from Stanford last summer, “[a]lthough the report clearly refutes the allegations of fraud and misconduct that were made against me,” the investigation itself had become so big a distraction that he decided to step down “for the good of the University.”
Investors don’t seem bothered by the events. They say they’re confident that Tessier-Lavigne — who left Genentech in 2011 to lead Rockefeller University, then joined Stanford in 2016 — is the right person for the job.
“I have known Marc for many years and know him to be a person of integrity and scientific vision who will be an exceptional CEO,” Nelsen said in an email. “Stanford exonerated him of any wrongdoing or scientific misconduct.”
Share:
Nvidia backs MetAI, a Taiwanese startup that creates AI-powered digital twins
Nvidia has been doubling down on the opportunity to build robotics and other industrial AI applications, with the launch of its Omniverse platform, and most recently Mega, an Omniverse Blueprint framework to create digital twins to operate these applications. It’s also investing in digital twin startups to get the effort off the ground. Taiwan’s MetAI has developed a model that can quickly generate “SimReady” (simulation-ready) digital twins using AI and 3D technology, by converting CAD files
Jan 15, 2025
Intel spins off its corporate venture arm, Intel Capital, into a standalone fund
Intel says that it plans to spin off its corporate venture arm, Intel Capital, into a standalone fund, with Intel as an “anchor investor.” In a press release on Tuesday, Intel said that the move will “[enable] greater autonomy” and “the flexibility to attract external capital.” Intel expects Intel Capital to begin operating independently in the second half of 2025, at which point it’ll be rebranded. The existing Intel Capital team will move to the new fund, and business operations will continue
Jan 14, 2025
Google-backed Pixxel launches India’s first private satellite constellation
Pixxel, an Indian space tech startup, has successfully launched the first three hyperspectral satellites of its commercial constellation Firefly aboard a SpaceX rocket from California, marking a significant milestone for India’s growing space ambitions. India is home to around 300 space startups and has gained worldwide attention for recent developments, including the successful landing of its lunar spacecraft on the south pole, the launch of a coronagraphy spacecraft, and partnering with NASA
Jan 14, 2025
Don't miss our latest news and updates. Subscribe to the newsletter